Overview
Virtual Event
Click Here to View the Program (PDF as of October 10th)
Under the theme of “New Challenges, New Solutions: to overcome with people all over the world together”, this year’s JAM will provide opportunities for stakeholders from industry, government, academia, and patient bodies to look back at what we have accomplished and learned during the COVID-19 pandemic and engage in deeper dialogues as we move to the next stage.
This year’s conference will be held entirely online through a fully integrated platform offering live and on-demand content, 1-2-1 chat and Community meetups, live Q&A during sessions and much more! Sessions will also be available to view for one month following the live event. Breaking walls and boundaries, the virtual platform will enable you to join the event from wherever you may be and to connect with fellow professionals from across the world.
.
Program Committee
-
E. Stewart Geary, MD • Senior Vice President
Eisai Co., Ltd., Japan -
Rie Matsui, RPh • Senior Director, Regional Labeling Head for APAC
Japan -
Katsuhiko Ichimaru • Review Director, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Kazuhiko Ishida, MSc, RPh • Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Tomoyuki Kakizume, PhD • Statistical & Quantitative Sciences
Takeda Pharmaceutical Co. Ltd.,, Japan -
Miyuki Kaneko • Japan Regulatory Portfolio Lead, Regulatory Affairs
Pfizer R&D Japan G.K., Japan -
Yukihiro Matsuda, MSc • Project Manager, Project Leadership
PRA Health Sciences K.K., Japan -
Yukiko Nishimura, PhD, MSc • President
NPO ASrid, Japan -
Mika Ogasawara • Data Quality Lead, Biometrics and Data Management
Pfizer R&D Japan G.K., Japan -
Takashi Sato, MSc, PMP •
PM Orchestra Takashi Sato, Japan -
Katsuhiko Sawada, MPharm • Director, Research and Development Dept.
Otsuka Medical Devices Co.Ltd., Japan -
Kazuyuki Suzuki, MSc • Oncology Trial Management Group, Trial Management Department, Japan Development
Novartis Pharma K.K., Japan -
Keiko Tsumori, MSc • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Nariaki Uemura • Development Project Management, Development
Astellas Pharma Inc., Japan -
Tadashi Urashima, PhD • Performance and Digital Analytics Lead, Medical & Development Excellence Japan
GlaxoSmithKline K.K., Japan -
Koichiro Yuji, MD, PhD, FACP • Project Associate Professor, The Institute of Medical Science
Japan -
Keiichi Inaizumi, MSc • Clinical Project Management Group/ Japan Clinical Project Manager
Pfizer R&D Japan, Japan -
Junichi Nishino, MSc, RPh • Head, Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Hironobu Saito, PhD • Corporate Officer /Head of Medical Affairs Div.
Daiichi Sankyo Co., Ltd., Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Atsushi Tsukamoto, PhD, MSc • Vice President, New Drug Regulatory Affairs Department
Daiichi Sankyo Company, Limited, Japan